Advertisement
Advertisement
U.S. markets open in 7 hours 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dyadic International, Inc. (DYAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2200+0.0700 (+2.22%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close3.1500
Open3.1900
Bid0.0000 x 900
Ask0.0000 x 1200
Day's Range3.1500 - 3.2300
52 Week Range1.7400 - 6.8900
Volume24,620
Avg. Volume59,511
Market Cap91.011M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-0.4380
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DYAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dyadic International, Inc.
    Analyst Report: Charles River Laboratories IntCharles River Laboratories is a non-clinical contract research organization (CRO), providing drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, and the Asia Pacific region. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). CRL provides services in basic research, drug discovery, safety and efficacy assessment, clinical support, and manufacturing for a wide range of pharmaceutical and biotech customers. The company is headquartered in Wilmington, Massachusetts.
    Rating
    Fair Value
    Economic Moat
    17 hours agoArgus Research
View more
  • GlobeNewswire

    Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

    JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary and patented microbial technologies to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, proteins, enzymes, certain metabolites and other biologic products at flexible commercial scales, today announced that its management an

  • GlobeNewswire

    Dyadic to Participate in Three Upcoming Industry Events

    JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and alternative food proteins and growth factors at flexible commercial scales, today announced that its management and representatives will

  • GlobeNewswire

    Dyadic to Present at 2022 Jefferies Healthcare Conference

    JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its Chief Executive Officer, Mark Emalfarb will present at the 2022 Jefferies Heal

Advertisement
Advertisement